Veru Inc VERU 深 沪
已收盘 02-06 16:00:00 美东时间
2.34
+0.100
+4.46%
华盛通- 最 高2.37
- 今 开2.24
- 成交量 6.59万股
- 最 低 2.21
- 昨 收 2.24
- 总市值 3755.77万
- 52周最高 7.40
- 市盈率 静 --
- 换手率 0.41%
- 52周最低 2.10
- 委 比 50.00%
- 总股本 1605.03万
- 历史最高 245.70
- 量 比 0.54
- 振 幅 7.14%
- 历史最低 2.14
- 每 手 1
- 风险率 1.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an
Veru Inc. kündigt Veröffentlichung von Quartalsergebnissen und Geschäftsupdate an Veru Inc. wird am 11. Februar 2026 die Finanzergebnisse für das erste Quartal des Geschäftsjahres 2026 veröffentlichen. Die Ergebnisse werden im Rahmen einer Telefonkonferenz und eines Audio-Webcasts präsentiert, die u
02-04 21:31
Veru Inc. to Announce Fiscal 2026 First Quarter Financial Results
Veru Inc. to Announce Fiscal 2026 First Quarter Financial Results Veru Inc. will report its fiscal 2026 first quarter financial results on February 11, 2026. The results will be discussed during a conference call and audio webcast at 8:00 a.m. ET, accessible on the Home page and Investors page of th
02-04 21:31
Veru Inc. gibt Termin für Aktionärstreffen bekannt
Veru Inc. gibt Termin für Aktionärstreffen bekannt Veru Inc. hält am 12. März 2026 eine Aktionärsversammlung in Miami ab. Während der Versammlung werden verschiedene Vorschläge zur Abstimmung gestellt, darunter auch der sogenannte Adjournment Proposal, der eine mögliche Vertagung der Versammlung zur
02-04 06:42
Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting
Veru Inc. Announces Date for Upcoming Annual Shareholders Meeting Veru Inc. has announced that its Annual Meeting of Shareholders will be held on March 12, 2026, at its Miami location. During the meeting, shareholders will vote on the election of six members to the Board of Directors, who will serve
01-29 05:07
Veru Inc. Earnings Call: Lean Mass Wins, Losses Mount
Veru Inc (($VERU)) has held its Q4 earnings call. Read on for the main highligh...
2025-12-23 08:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
Canaccord Genuity Initiates Coverage On Veru with Buy Rating, Announces Price Target of $25
Canaccord Genuity analyst Edward Nash initiates coverage on Veru (NASDAQ:VERU) with a Buy rating and announces Price Target of $25.
2025-12-18 20:50
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
Veru Inc. announced positive results from the Phase 2b QUALITY study of enobosarm in combination with GLP-1 RA, showing significant fat loss and lean mass preservation. The FDA has provided regulatory clarity, supporting incremental weight loss as a potential approval endpoint. Veru plans to initiate the Phase 2b PLATEAU study in Q1 2026, targeting older patients with obesity. Following the fiscal year end, the company completed a public offering...
2025-12-17 11:30
Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop
Veru Inc., a late clinical stage biopharmaceutical company, announced multiple presentations at the 18th SCWD International Conference and Regulatory Workshop in Rome. Mitchell Steiner, Veru's Chairman, President & CEO, will present on weight loss drugs, novel strategies for sarcopenia and obesity, treatment approaches for muscle wasting, and regulatory considerations. Veru is developing enobosarm, a selective androgen receptor modulator, to enha...
2025-12-04 13:30
